Jump to main content
Jump to site search


NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors

Author affiliations

Abstract

An aptamer-conjugated gold nanostar (dsDDA–AuNS) has been developed for targeting nucleolin present in both tumor cells and tumor vasculature for conducting a drug-resistant cancer therapy. AuNS with its strong absorption in the near-infrared (NIR) region was assembled with a layer of the anti-nucleolin aptamer AS1411. An anticancer drug, namely doxorubicin (DOX), was specifically conjugated on deoxyguanosine residues employing heat and acid labile methylene linkages. In response to NIR irradiation, dsDDA–AuNS allowed on-demand therapeutics. AS1411 played an active role in drug cargo–nucleus interactions, enhancing drug accumulation in the nuclei of drug-resistant breast cancer cells. The intravenous injection of dsDDA–AuNS allowed higher drug accumulation in drug-resistant tumors over naked drugs, leading to greater therapeutic efficacy even at a 54-fold less equivalent drug dose. The in vivo triggered release of DOX from dsDDA–AuNS was achieved by NIR irradiation, resulting in simultaneous photothermal and chemotherapeutic actions, yielding superior tumor growth inhibition than those obtained from either type of monotherapy for overcoming drug resistance in cancers.

Graphical abstract: NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors

Back to tab navigation

Supplementary files

Article information


Submitted
09 Nov 2019
Accepted
17 Jan 2020
First published
22 Jan 2020

Biomater. Sci., 2020, Advance Article
Article type
Paper

NIR-cleavable drug adducts of gold nanostars for overcoming multidrug-resistant tumors

A. C. del Valle, C. Su, Y. Sun and Y. Huang, Biomater. Sci., 2020, Advance Article , DOI: 10.1039/C9BM01813A

Social activity

Search articles by author

Spotlight

Advertisements